CPG Term Sheet Traps: The Investor Clauses That Can Cost You Everything at Exit

It was July 2015. We were three months into negotiating what should have been one of the great moments of any founder's career — a partnership deal with Coca-Cola, valuing Suja at $300 million.

Coke was committed to $90 million. Our angels — the people who had written personal checks when Suja was still just cold-pressed juice bottles in a San Diego ice closet — were about to get wiped out.

Not because Coke wanted to hurt them. Not because the deal was bad. Because years earlier, when we needed institutional capital, we had signed a term sheet with a private equity firm called ACG that gave them first-money-out preference on any liquidity event. ACG had been in the deal for less than twelve months. Our angels had been in for three years.

The math was brutal. Coke's $90 million would have flowed almost entirely to ACG first — a firm that had barely met these people — while the investors who had taken a leap of faith on us got almost nothing.

That's what liquidation preference does. And if you don't understand it before you sign your next term sheet, it's going to do it to you too.

I've been involved in forty-four fundraising rounds across eight companies. I've seen term sheets from angels, seed funds, venture capital, growth equity, and Fortune 500 strategic investors. And here's what I've learned: the term sheet that wins your raise isn't always the term sheet that serves you at exit.

Most founders read a term sheet and focus on the valuation. What's my company worth? That's the wrong question — or at least, it's not the only one. The better question is: Under what circumstances do I actually get to keep that number?

The answer lives in the clauses most founders gloss over. The ones the lawyer explains in two paragraphs. The ones that feel abstract right up until the moment they're not.

Let me walk you through the ones that actually matter.

Liquidation Preference: The Clause That Protects Investors First

Every institutional investor — and most sophisticated angels — will ask for a liquidation preference. This means in any sale, merger, or liquidation event, they get paid back before you do.

That's not inherently bad. Investors take risk. They should have some protection. The question is how much protection, and what form it takes.

Here's the spectrum:

1x non-participating preferred. The investor gets their money back first, then converts to common stock and participates alongside founders in whatever's left. This is founder-friendly. If the company sells for 3x, the investor chooses: take 1x or convert to equity and take 3x. They'll convert. You both win.

1x participating preferred. This is where it gets expensive. The investor takes their 1x back and participates in the remaining proceeds as if they were holding common. They get paid twice — once as a preferred holder and once as a common shareholder. This is the clause that quietly extracts millions from a founder's exit without ever looking like a red flag.

2x or higher participating preferred. Now you're paying back twice the original investment before a dollar goes to founders. In a down round or a below-expectations exit, this can eliminate founders entirely.

When we were negotiating the Coke deal, ACG's participation rights were eating the first slug of liquidity. It was their contractual right. I don't begrudge them the clause — we signed it. But it was also my right to fight back.

So we went and found Goldman Sachs' $60 million. We restructured the deal so our angels could sell roughly 40% of their holdings at an average 3.4x return while keeping 60% of their equity. Later — when Suja eventually sold — those same angels got a second bite of the apple. Their total return came to roughly 10x their original investment.

It didn't have to end that way. Most founders don't fight that hard. Most of the time, the preference stack just plays out.

"Deals are not just about valuations. They are about fairness and morale."

The Preference Stack: What Happens When You Have Multiple Rounds

Here's the problem most founders don't see coming. You raise a seed round. Then a Series A. Then a Series B. Each round likely has some version of a liquidation preference.

Now those preferences stack. When a liquidity event happens, investors get paid in reverse chronological order — newest money first, oldest money last, founders at the bottom.

If your Series B investor has 2x participating preferred and came in at a $30 million valuation, they take $60 million before anyone else sees a dollar. Your Series A investor takes their preference next. Your seed investors are next. You're last.

In a moderate exit — say 2x revenue — the preference stack can wipe out founders almost entirely. The company grows from zero to a successful acquisition, and the person who built it walks away with less than someone who wrote a check eighteen months before the deal closed.

I've seen this happen. I've seen founders who deserved eight-figure exits walk away with single-digit millions because they didn't model out the waterfall before they signed three different term sheets.

What to do about it:

Before you sign any new round, run the waterfall. Model your exit at 2x, 4x, and 6x revenue. Plug in every preference stack. Know exactly what you receive at each exit scenario before you accept the valuation.

Preference stacks are negotiable. Not always easy, but negotiable. Push for 1x non-participating preferred wherever you can. When you can't, at least understand what you're giving up.

Anti-Dilution: The Clause That Punishes You for a Down Round

Anti-dilution provisions protect investors if you raise money at a lower valuation in a future round. The investor's share price gets adjusted downward — meaning they get more shares — to compensate.

There are two flavors:

Broad-based weighted average. The adjustment is blended across the entire cap table. Painful, but proportional. This is the standard and the more founder-friendly version.

Full ratchet. The investor's price gets reset to the new, lower price on every share they own, regardless of how many shares are newly issued. If they paid $5/share and you do a down round at $2/share, they get new shares at $2 for everything they already owned. This can cause catastrophic dilution for founders and all other shareholders.

Full ratchet anti-dilution is rare in early rounds, but it surfaces in down-round bridge financing, rescue capital situations, and deals where founders are desperate. If you see it, understand exactly what you're accepting.

The Rule of Twos applies here: everything in CPG takes twice as long and costs twice as much as you think. Which means down rounds happen more than any of us want to admit. Know what anti-dilution clause you have before that happens, not after.

Board Control: Who Actually Runs Your Company

The board governance section of a term sheet is where investors take seats. This is worth reading very carefully.

A typical early-stage CPG company might have three board seats: two founders, one investor. Add a Series A, you might have five: two founders, one seed investor, one Series A investor, one independent. Series B comes in, wants a seat. Now the founders are outvoted.

Here's what board control actually means in practice: approval rights over major decisions. Budget approval. Hiring and firing the CEO. Selling the company. Taking on debt. These are typically called protective provisions — a list of actions the board (or a specific investor class) must approve.

Read the protective provisions list carefully. Some are reasonable — major debt, acquisitions over a certain size. Some can effectively give an investor veto power over your business on a daily basis.

The question isn't just how many seats an investor gets. It's what specific decisions require their approval, and what threshold of the board makes those decisions.

When Coca-Cola came into Suja, board dynamics changed significantly. "For the first time in my career, I found myself operating without that same sense of collective confidence." Not because Coke was adversarial — they weren't. But the governance structure shifted. Decision cycles got longer. Pre-meetings became a thing. That's the reality of institutional board control, and it's worth understanding before you grant it.

Pro-Rata Rights: The Clause That Looks Like a Compliment

Pro-rata rights give an investor the right to participate in future rounds to maintain their ownership percentage. On the surface this sounds fine — maybe even flattering. My investor wants to keep investing in me.

Here's where it gets complicated. Pro-rata rights can affect the composition of your future rounds. If a prior investor has pro-rata rights and your new lead investor wants to own 20% of the company, the new investor may balk if 15% of that 20% allocation is already spoken for.

Lead investors for a Series B or growth round typically want to own a meaningful chunk. If your cap table is cluttered with pro-rata right holders all exercising their rights at the same time, you end up either diluting the new lead below their target, triggering a difficult negotiation, or shutting out investors who want in.

Manage your pro-rata commitments carefully. Know who has them. Know which investors will actually exercise them and which ones won't. And when you're negotiating future rounds, be upfront with new investors about what's already committed.

Information Rights: The Covenant That Follows You

Information rights clauses require you to send investors regular financial reports — monthly or quarterly financials, annual audited statements, board meeting minutes, sometimes a budget.

Most founders sign these without thinking twice. Of course I'll keep my investors informed. Yes. But there's a difference between keeping investors informed and contractually obligating yourself to an investor who just bought a small stake in a convertible note.

Information rights in the wrong hands can:

Complicate a sale if a buyer discovers your investor list includes someone the acquirer has had problems with
Create confidentiality risks if an investor shares your financials with a competitor
Generate legal exposure if you miss a reporting deadline during a chaotic operational period

Negotiate for proportional information rights. Major investors who own significant equity deserve full access. Small check writers and bridge lenders may only need basic annual statements.

The Conversation You Need to Have Before You Close

Here's the summary framework I've used across forty-four rounds:

Before signing any institutional term sheet, answer these questions:

What is the preference structure, and at what exit multiples does it stop hurting me?
If I raise a down round — or go through a bridge — what does anti-dilution do to my ownership?
What decisions require board or investor approval, and what are the thresholds?
Which investors have pro-rata rights, and will they actually exercise them?
Who has information rights, and am I comfortable with everything that commitment implies?

Then model the waterfall. Not just at the valuation you're targeting. At half of it. At a fire-sale number. Know where every dollar goes before you sign.

Your lawyer can walk you through the mechanics, but don't outsource the judgment. You have to understand this. Because the term sheet is a prediction about a future you haven't lived yet, and the terms that seem theoretical in year one become very real in year four.

Hope is not a strategy. And it's definitely not a term sheet.

The angels who invested in Suja before we had distribution, before we had real revenue, before we knew whether cold-pressed juice was a category or a trend — they took a genuine risk. They deserved their return.

Fighting for them cost us months of delay on the Coke deal. It cost me political capital and difficult conversations with ACG. It was worth every bit of it.

"Deals are not just about valuations. They are about fairness and morale."

Understand your term sheet. Fight for the people who believed in you. And build a cap table you'd be proud to defend at the exit table.

If you're preparing for a fundraise and want to stress-test your capital strategy before you talk to investors, the 90-Day Breakthrough program walks through term structure, cap table modeling, and investor negotiation as part of the full fundraising playbook. And for a deeper dive into the financial mechanics that determine whether your business is investable, check out the CPG MBA.